1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transplant strategies in relapsed/refractory Hodgkin lymphoma
    Journal Article

    Shah, G. L.; Moskowitz, C. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
    Journal Article

    Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Illidge, T.; Uttarwar, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • CARs and other T cell therapies for MM: The clinical experience
    Journal Article

    Danhof, S.; Hudecek, M.; Smith, E. L.
    Best Practice and Research: Clinical Haematology (2018)

    Fulltext@MSK | Save
  • Money-back guarantees for expensive drugs: Wolf's clothing but a sheep underneath
    Journal Article

    Mailankody, S.; Bach, P. B.
    Annals of Internal Medicine (2018)

    Fulltext@MSK | Save
  • A randomized, open-label, multicenter phase 2 study of daratumumab monotherapy for patients (Pts) with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus
    Meeting Abstract

    Cavo, M.; Hofmeister, C. C.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J.; Venner, C.; Sandhu, I.; Jenner, M.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • A comparison of immune reconstitution following human placenta-derived stem cells (HPDSC) with umbilical cord blood transplantation (UCBT) vs. UCBT alone in pediatric recipients with malignant and non-malignant diseases
    Meeting Abstract

    Sandhu, S.; Flower, A.; Geyer, M.; Harrison, L.; Shi, Q.; Pulsipher, M.; Giller, R.; Morris, E.; Klejmont, L.; Ayello, J.; more...
    Journal of Clinical Immunology (2018)

    Fulltext@MSK | Save
  • Targeting B-cell maturation antigen (BCMA) with GSK2857916 antibody-drug conjugate provides durable responses in patients (Pts) with heavily-pretreated relapsed/refractory multiple myeloma (RRMM): Preliminary results from study BMA117159
    Meeting Abstract

    Popat, R.; Trudel, S.; Lendvai, N.; Voorhees, P.; Reeves, B.; Libby, E.; Richardson, P.; Anderson, L. Jr; Sutherland, H.; Yong, K.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Melflufen therapy for heavily pretreated relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: Early efficacy data (Horizon)
    Meeting Abstract

    Mateos, M. V.; Oriol Rocafiguera, A.; Rodríguez-Otero, P.; Bladé, J.; Larocca, A.; Moreb, S. J.; Cavo, M.; Mazumder, A.; Alegre, A.; Hassoun, H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin Lymphoma from the phase 2 CheckMate 205 study
    Meeting Abstract

    Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G. P.; Fanale, M. A.; Armand, P.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP) with stable deep molecular response (DMR) discontinuing dasatinib (DASFREE)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutierrez, J. V.; Jimenez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gomez-Casares, M. T.; Pane, F.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save